Savara's Molgramostim Shows Long-Term Efficacy in Autoimmune Pulmonary Alveolar Proteinosis Patients
Savara Inc., a clinical-stage biopharmaceutical company, has presented long-term efficacy and safety data from the ongoing IMPALA-2 Phase 3 clinical trial at the American Thoracic Society International Conference 2026. The trial evaluates molgramostim, an inhalation solution, for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The study involves 164 patients and is the largest of its kind for aPAP. During the open-label (OL) treatment period, all patients received molgramostim, and the data showed continuous improvements in pulmonary gas transfer and respiratory health-related quality of life (HRQoL). The trial's lead clinical investigator, Dr. Bruce Trapnell, highlighted the high patient retention rate and the drug's tolerability over time. 
